Potomac horse fever review points to broader global distribution

Potomac horse fever may need a broader map. A new systematic review in Veterinary Research Communications synthesizes the global literature on Neorickettsia risticii, the causative agent classically associated with Potomac horse fever, and lands at a familiar but important conclusion: the pathogen’s known range extends well beyond the mid-Atlantic origin story that shaped the disease’s name. That message is reinforced by a 2026 open-access review in Veterinary Microbiology, which describes equine neorickettsiosis as endemic in multiple regions of the US and Canada, with documented occurrence in Brazil and Uruguay as well. (sciencedirect.com)

The backdrop here is a disease ecology that has always complicated surveillance. Neorickettsia species are obligate endosymbionts of digenean trematodes, with life cycles involving aquatic snails and other intermediate hosts, including aquatic insects that horses may ingest accidentally. That means exposure risk is shaped by waterways, insect ecology, seasonality, and local parasite-host dynamics, not simply by state or national borders. Merck notes the disease is most often seen in spring through early fall and is associated with pastures bordering creeks or rivers. (sciencedirect.com)

The newer literature also reflects a taxonomic and epidemiologic shift. Potomac horse fever is no longer viewed as a single-agent story: AAEP and recent reviews note that Neorickettsia findlayensis can cause a similar syndrome, and a 2022 diagnostic paper highlighted the need for assays that better distinguish among Neorickettsia species. In that study, investigators described a duplex real-time PCR approach intended to improve N. risticii detection, while also underscoring that additional work is needed to define the geographic distribution and prevalence of Neorickettsia species causing disease in horses. (aaep.org)

That diagnostic point may be one of the most practical implications of the review. Serology has long been used as evidence of exposure, but both Merck and the PCR paper caution that indirect fluorescent antibody testing can generate false-positive results and is of limited value for definitive diagnosis in individual horses. Current guidance instead favors PCR on blood and feces, particularly because organism detection may not coincide across sample types, and because rapid confirmation can support earlier treatment decisions. (merckvetmanual.com)

Industry guidance remains cautious on prevention. AAEP classifies Potomac horse fever vaccination as risk-based rather than core, and says veterinarians may consider more frequent revaccination in endemic areas because protection can be incomplete and short-lived. Merck similarly states that available inactivated whole-cell vaccines have been only marginally protective in the field, with strain and genomic heterogeneity among isolates cited as one likely reason. That aligns with the broader literature’s emphasis on antigenic diversity as a barrier to durable prevention. (aaep.org)

Why it matters: For veterinary professionals, this review is a reminder that disease labels can lag behind disease ecology. In practice, that means keeping equine neorickettsiosis on the differential list outside the classic Potomac corridor, especially in horses with acute fever, enterocolitis, laminitis, or abortion risk and a plausible environmental exposure history. It also strengthens the case for discussing local water-associated risk with pet parents, using PCR earlier in workups, and setting realistic expectations that vaccination may reduce risk but won’t eliminate it. Early oxytetracycline treatment remains important, with prognosis improving when therapy starts before severe complications develop. (merckvetmanual.com)

Expert reaction in the formal sense was limited in the publicly accessible material reviewed, but the consensus across AAEP guidance, Merck, and recent diagnostics literature is consistent: this is a geographically broader, diagnostically trickier disease than many clinicians were taught, and improved molecular surveillance is still needed. That’s especially relevant as case reports and pathogen detections continue to surface beyond historically emphasized regions, including Canada and Brazil. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next meaningful developments will likely come from better geographic surveillance, more routine species-specific PCR testing, and vaccine research aimed at broader protection against diverse Neorickettsia strains, including N. findlayensis as well as N. risticii. (pmc.ncbi.nlm.nih.gov)